Current progress towards the development of tyrosine kinase inhibitors as anticancer agents

Emerging Drugs

Volumn 3, Issue , 1998, Pages 279-292

  Bridges, A J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4,5 BIS(4 FLUOROANILINO)PHTHALIMIDE; ANTINEOPLASTIC AGENT; BE 23372; CGP 59326; DAP 720; ERLOTINIB; GEFITINIB; GW 282974; ISOENZYME; LEFLUNOMIDE; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; PD 161570; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; UNCLASSIFIED DRUG; WIN 41662;

ANTINEOPLASTIC ACTIVITY; CELL PROLIFERATION; DRUG DESIGN; HUMAN; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0031957879     PISSN: 13619195     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.3.1.279     Document Type: Review

References (30)